Talniflumate (Genaera)

Overview

Journal Curr Opin Investig Drugs

Specialties Infectious Diseases
Pharmacology

Date 2004 Jun 19

PMID 15202731

Citations 8

Authors

Darryl Knight

Affiliations

Soon will be listed here.

Abstract

Talniflumate, an anti-inflammatory molecule that was originally developed by Laboratorios Bago, is currently being developed by Genaera as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. Phase I trials with talniflumate had been completed by August 2001, and phase II trials were underway in Ireland for the treatment of cystic fibrosis.

Citing Articles

Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease.

Liu Y, Liu T, Zhou Y, Li W, Wang M, Song N Acta Pharm Sin B. 2023; 13(2):662-677.

PMID: 36873178 PMC: 9978855. DOI: 10.1016/j.apsb.2022.07.021.

Cu(I)- and Pd(0)-Catalyzed Arylation of Oxadiamines with Fluorinated Halogenobenzenes: Comparison of Efficiency.

Lyakhovich M, Averin A, Grigorova O, Roznyatovsky V, Maloshitskaya O, Beletskaya I Molecules. 2020; 25(5).

PMID: 32121113 PMC: 7179129. DOI: 10.3390/molecules25051084.

Screening study for genetic polymorphisms affecting pharmacokinetics of talniflumate.

Jin L, Kim B, Lee J, Lee K, Kwack K, Yim S Transl Clin Pharmacol. 2020; 25(4):166-172.

PMID: 32095470 PMC: 7033407. DOI: 10.12793/tcp.2017.25.4.166.

Catalytic asymmetric acetalization of carboxylic acids for access to chiral phthalidyl ester prodrugs.

Liu Y, Chen Q, Mou C, Pan L, Duan X, Chen X Nat Commun. 2019; 10(1):1675.

PMID: 30975988 PMC: 6459872. DOI: 10.1038/s41467-019-09445-x.

TMEM16A in Cystic Fibrosis: Activating or Inhibiting?.

Kunzelmann K, Ousingsawat J, Cabrita I, Dousova T, Bahr A, Janda M Front Pharmacol. 2019; 10:3.

PMID: 30761000 PMC: 6362895. DOI: 10.3389/fphar.2019.00003.